October 2025
The global checkpoint inhibitor biologics CDMO market is growing as demand rises for outsourced biologics development and scalable immuno-oncology manufacturing.
April 2026
The global immune checkpoint inhibitors market size is predicted to hit around USD 258.91 billion by 2035 from USD 58.53 billion in 2025 with a CAGR of 16.03%.
February 2026
The global biologics CDMO market size was valued at USD 23.08 billion in 2025 and is projected to hit around USD 55.11 billion by 2035 with a healthy CAGR of 9.14%.
July 2025
Explore the checkpoint inhibitor drugs market, driven by rising cancer prevalence, expanding indications for PD-1/PD-L1 and CTLA-4 inhibitors, and advancements in immuno-oncology therapies.
May 2026
Europe Pharmaceutical CDMO market size is projected to hit around USD 94.94 billion by 2035, rising from USD 45.68 billion in 2025, growing at a CAGR of 7.59%.
May 2026
The global calcineurin inhibitors market size was evaluated at USD 10.42 billion in 2025 and is predicted to hit around USD 20.88 billion by 2035, growing at a CAGR of 7.20%.
May 2026
The global active pharmaceutical ingredients CDMO market size is evaluated at USD 116.77 billion in 2025 and is predicted to hit around USD 231.48 billion by 2035, growing at a CAGR of 7.81%.
April 2026
The global chemical drug CDMO market size was evaluated at USD 13.20 billion in 2025 and is predicted to hit around USD 29.84 billion by 2035, growing at a CAGR of 8.50%.
April 2026
The global chemical API CDMO market size was evaluated at USD 16.80 billion in 2025 and is predicted to hit around USD 40.88 billion by 2035, growing at a CAGR of 9.30%.
April 2026
The global mRNA therapeutics CDMO market size is estimated to hit around USD 14.63 billion by 2035 from USD 5.09 billion in 2025, with a CAGR of 11.14%.
April 2026
The global proton pump inhibitors market size is estimated to hit around USD 7.33 billion by 2035 increasing from USD 4.29 billion in 2025, with a CAGR of 5.50%.
March 2026
The global cancer biologics market size was valued at USD 117.45 billion in 2025 and is expected to hit around USD 235.81 billion by 2035 with a CAGR of 7.22%.
March 2026
The orthobiologics market size was estimated at USD 7.37 billion in 2025 and is expected to surge around USD 12.55 billion by 2035, with a notable CAGR of 5.47%.
March 2026
The global biologics and biosimilars market size is estimated to hit around USD 2,426.85 billion by 2035 increasing from USD 610.41 billion in 2025, with a CAGR of 14.80%.
March 2026
The global live biotherapeutic products and microbiome CDMO market size is estimated to hit around USD 1,838.56 million by 2035 from USD 76.77 million in 2025, at a CAGR of 37.38%.
March 2026
The hormonal drug CDMO market is expanding with rising demand for outsourced development and manufacturing of therapies for endocrine and reproductive health.
March 2026
The global bispecific antibodies CDMO market expands with demand for next-generation therapeutics, advanced expression systems, and regulatory compliance expertise.
March 2026
The global pharmaceutical CDMO market size is calculated at USD 197.40 billion in 2025 and is projected to hit around USD 392.67 billion by 2035 with a CAGR of 7.12%.
March 2026
The global paraffin inhibitors market size was valued at USD 737.81 million in 2025 and is projected to hit around USD 1,180.61 million by 2035, at a CAGR of 4.81%.
February 2026
The interleukin inhibitors market size was exhibited at USD 30.62 billion in 2025 and is expected to surpass around USD 93.68 billion by 2035 with a CAGR of 11.83%.
February 2026
The global veterinary CRO and CDMO market size was valued at USD 7.73 billion in 2025 and is predicted to surpass around USD 17.15 billion by 2035 with a CAGR of 8.30%.
February 2026
The global cell cycle inhibitors market size was evaluated at USD 5.72 billion in 2025 and is predicted to hit around USD 11.50 billion by 2035, growing at a CAGR of 7.23%.
February 2026
The global bone resorption inhibitors market size was evaluated at USD 3.87 billion in 2025 and is predicted to hit around USD 7.48 billion by 2035, growing at a CAGR of 6.82%.
February 2026
The global aldose reductase inhibitor market size was evaluated at USD 6.81 billion in 2025 and is predicted to hit around USD 12.55 billion by 2035, growing at a CAGR of 6.30%.
February 2026
The global VMAT2 inhibitors market size was evaluated at USD 6.04 billion in 2025 and is predicted to hit around USD 15.29 billion by 2035, growing at a CAGR of 9.74%.
January 2026
The global investigational new drug CDMO market size is estimated to hit around USD 10.90 billion by 2035 from USD 5.61 billion in 2025, with a CAGR of 6.87%.
January 2026
The global plug-and-play CDMO market is growing rapidly as pharma and biotech firms seek flexible, scalable, and fast-track manufacturing solutions.
January 2026
The global biologics market was valued at USD 487 billion in 2025 and is expected to hit around USD 1243.80 billion by 2035, growing at a CAGR of 9.83%.
January 2026
The global radiopharmaceutical CDMO market size was evaluated at USD 3.24 billion in 2025 and is predicted to hit around USD 8.50 billion by 2035, growing at a CAGR of 10.12%.
November 2025
The global small molecule innovator CDMO market size is valued at USD 56.41 billion in 2025 and is projected to hit around USD 97.67 billion by 2034 with a CAGR of 6.29%.
+1 650 460 3308
+61 485 981 310 +91 87933 22019
sales@precedenceresearch.com